<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
RGEN
Repligen
$
()


  • Repligen participates in a conference call with JPMorgan

    5/9/2024 - 10:55am
  • Repligen participates in a conference call with JPMorgan

    5/9/2024 - 04:55am
  • Repligen participates in a conference call with JPMorgan

    5/6/2024 - 17:01pm
  • Repligen reports Q1 adjusted EPS 28c, consensus 30c

    5/1/2024 - 07:32am
  • Ingersoll-Rand's Dover deal not a threat to bioprocessing space, says KeyBanc

    3/25/2024 - 14:05pm
  • Repligen appoints Pax to board of directors

    3/19/2024 - 07:35am
  • Repligen price target raised by $50 at Craig-Hallum, here's why

    2/23/2024 - 09:14am
  • Repligen price target raised by $42 at Stifel, here's why

    2/22/2024 - 08:58am
  • Repligen reports Q4 adjusted EPS 33c, consensus 33c

    2/21/2024 - 07:34am
  • Repligen price target raised by $10 at KeyBanc, here's why

    2/15/2024 - 06:44am
  • Repligen announces data for odronextamab in R/R FL from Phase 2 trial

    12/10/2023 - 19:40pm
  • Repligen sees year-end cash, cash equivalents $717M-$727M

    12/7/2023 - 07:38am
  • Repligen reports private convertible transaction of senior notes

    12/7/2023 - 07:37am
  • Repligen downgraded to Hold from Buy at Benchmark

    12/4/2023 - 08:51am
  • Repligen announces publication of 2022 sustainability report

    11/14/2023 - 07:47am
dynamic_feed Breaking News